本文源自：金融界AI电报 石四药集团(02005.HK)公告，本集团的甲氧氯普胺及盐酸甲氧氯普胺已获中国国家药品监督管理局批准 登记成为在上市制剂使用的原料药。两款原料药属于多巴胺受体D2拮抗剂，同时还具有5-羟色胺4（5- HT4）受体激动效应，促进胃肠动力，主要用于止吐及治疗恶心、嗳气、胃部胀满、返流性食管炎等疾 病。 ...

石四药集团(02005)发布公告，本集团的甲氧氯普胺及盐酸甲氧氯普胺已获中国国家药品监督管理局批 准登记成为在上市制剂使用的原料药。 两款原料药属于多巴胺受体D2拮抗剂，同时还具有5-羟色胺4(5-HT4)受体激动效应，促进胃肠动力，主 要用于止吐及治疗恶心、嗳气、胃部胀满、返流性食管炎等疾病。 ...

Group 1 - The company Shijiazhuang Four Medicines Group (stock code: 02005) announced that its Metoclopramide and Hydrochloride Metoclopramide have been approved by the National Medical Products Administration of China for registration as active pharmaceutical ingredients for use in marketed formulations [1] - Both active pharmaceutical ingredients are classified as dopamine receptor D2 antagonists and also exhibit 5-hydroxytryptamine 4 (5-HT4) receptor agonist effects, promoting gastrointestinal motility [1] - The primary applications of these drugs include antiemetic treatment and management of nausea, belching, abdominal distension, and gastroesophageal reflux disease [1]